Top Companies in Cell and Gene Therapy
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top Companies in Cell and Gene Therapy
Cell and Gene Therapy News
Autologous and Allogeneic Models Push Cell Therapy Toward Different Development Paths
Thursday, October 22, 2026
Cell therapy product development is becoming more segmented as autologous and allogeneic products place different demands on design, manufacturing and commercialization. Developers can no longer discuss the sector as one uniform category. Product strategy depends heavily on whether cells come from the patient or from a donor source. Autologous therapies are often built around individualized production. A patient’s own cells are collected, processed and returned as a therapy. This model can create a strong biological fit, but it also places pressure on scheduling, chain of identity, release timelines and site coordination. Every patient-specific batch becomes both a treatme
Immune Oncology: Cancer Care through Precision Immunotherapy and Scientific Innovation
Monday, October 12, 2026
Immune oncology therapies boost or modify immune responses to better recognize the cancer and also help to control the disease for the long term. This approach has broadened treatment options for multiple types of cancer and continues to spur innovation in research, drug development, diagnostics and personalized healthcare. Immune oncology encompasses a variety of treatment strategies, including immune checkpoint inhibitors, cancer vaccines, adoptive cell therapies, cytokine therapies, oncolytic viruses, monoclonal antibodies and combination treatment strategies. Revolutionizing Cancer Care with Innovative Technology Advances Technological innovations
Cell Therapy Developers Put Manufacturing Strategy Earlier in the Pipeline
Monday, September 28, 2026
Cell therapy product development is becoming more manufacturing-led as companies recognize that clinical promise can weaken if process design is not addressed early. Developers are moving beyond a research-first mindset and placing greater attention on scalability, product consistency, release testing and manufacturing evidence before late-stage trials. The market context supports this shift. The global cell therapy manufacturing market is estimated at USD 6.51 billion in 2026 and is projected to reach USD 17.65 billion by 2033, according to Coherent Market Insights. Growth is being shaped by demand across autologous and allogeneic therapies, along with development activity in o
Hospital-Based Stem Cell Programs Highlight the Access Challenge
Wednesday, September 09, 2026
Stem cell treatment centers are becoming more important in regions where patients need complex transplant services but must travel far from home for care. While public attention often focuses on regenerative medicine clinics, established stem cell treatment is most mature in areas such as blood cancers and serious blood disorders, where transplant programs require specialized hospital infrastructure. A recent report from Australia described a campaign to establish a donor stem cell transplant service at Townsville University Hospital. The initiative aims to reduce the need for patients in North Queensland to travel to Brisbane for Total Body Irradiation before some stem cell tra
Evidence before Expansion in Stem Cell Therapy
Wednesday, September 09, 2026
Stem cell therapy purchasing decisions rarely turn on whether a clinic can offer treatment. The harder question is whether the protocol produces evidence that management teams can interpret and compare over time. Variation in cell sourcing and preparation makes that difficult. Some clinics combine multiple biologic products or alter methods from case to case, leaving no clear way to separate treatment effect from patient selection. For a referral network or clinical partner, that uncertainty can become a governance problem rather than a scientific detail. Protocol discipline deserves close attention. A consistent method doe
Advancing the Future of Personalized Gene Therapy and Cancer Treatment
Tuesday, September 01, 2026
Gene therapy and cancer solutions are transforming the landscape of modern healthcare by introducing innovative approaches to manage various forms of cancer. As scientific understanding of genetics and cellular behavior continues to expand, healthcare researchers and biotechnology organizations are developing therapies that target cancer at its biological source rather than relying solely on conventional treatment methods. These advancements are creating new possibilities for personalized medicine, improved treatment outcomes, and more precise therapeutic interventions. Researchers are increasingly exploring genetic-based solutions that address the underlying mechanisms responsi
